ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday morning. The company provided EPS guidance of 5.06-5.23 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.14. The company issued revenue guidance of $209-212 million, compared to the consensus revenue estimate of $209.67 million.
A number of analysts have recently weighed in on ANIP shares. ValuEngine raised shares of ANI Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, November 19th. Guggenheim started coverage on ANI Pharmaceuticals in a report on Thursday, September 12th. They issued a buy rating and a $76.00 target price on the stock. Zacks Investment Research lowered ANI Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, November 12th. Finally, BidaskClub raised ANI Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. ANI Pharmaceuticals currently has a consensus rating of Hold and an average target price of $86.40.
ANIP opened at $59.43 on Tuesday. The company’s 50 day moving average is $67.04 and its 200-day moving average is $72.11. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $86.96. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.30. The company has a market cap of $744.99 million, a P/E ratio of 12.89 and a beta of 1.96.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
See Also: What is net income?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.